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Abstract
Background: Hepatocellular carcinoma (HCC) remains a major public health problem worldwide. The identification
of effective chemotherapeutic targets for advanced HCC patients is urgently required. In this study, we investigated
the role of protein phosphatase 2A-B55δ subunit (PP2A-B55δ, encoded by the PPP2R2D gene) and related
mechanisms affecting chemotherapy sensitivity of HCC.
Methods: Experimental approaches for measuring the levels of PPP2R2D mRNA and B55δ protein in HCC included
bioinformatics analyses, quantitative real-time polymerase chain reaction (qRT-PCR), western blotting (WB),
immunofluorescence and immunohistochemistry assays. Cell cycle, migration, colony formation, apoptosis, and
cell proliferation assays in stable PPP2R2D-knockdown and -overexpression cell lines in vitro, and tumorigenicity
assays in vivo, were performed to explore the function of B55δ in cisplatin (cDDP) chemotherapy of HCC.
Bioinformatics prediction, luciferase reporter assays, qRT-PCR, WB, and cell cycle analyses were used to reveal
the regulatory relationship between microRNA-133b (miR-133b) and PPP2R2D expression. miR-133b mimic and
inhibitor were used to elucidate the regulatory mechanism.
Results: Our studies showed that PPP2R2D expression was down-regulated in both HCC tumors and HCC cell
lines. Treatment with cDDP increased the amount of B55δ protein. Artificially increasing the expression of B55δ
counteracted cyclin-dependent kinase 1 activation, modulated transitions of the cell cycle, and increased the
suppressive effect of cDDP on cell migration, colony formation, apoptosis, and proliferation in vitro and tumor
growth in vivo, thus enhancing therapeutic efficiency. In contrast, knockdown of B55δ partially inhibited the effect of
cDDP chemotherapy. miR-133b was shown to regulate PPP2R2D expression by binding to the 3’-untranslated
region of PPP2R2D mRNA. The miR-133b/PPP2R2D signaling pathway affects the effectiveness of cDDP chemotherapy.
Conclusions: PP2A-B55δ, regulated by miR-133b, enhances the sensitivity of HCC to cDDP chemotherapy. Our data
indicate that PP2A-B55δ might be a novel and attractive target for increasing chemotherapy sensitivity of HCC.
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Background
According to global cancer statistics, about 782,500 new
liver cancer cases occurred worldwide in 2012, together
with about 745,500 deaths [1]. Seventy to 90 % of primary
liver cancers are hepatocellular carcinoma (HCC). Since
patients are asymptomatic at the early stages of the dis-
ease, HCC is mostly diagnosed at an advanced stage [2].
Moreover, the effectiveness of anti-cancer treatment varies
considerably among different HCC patients. Therefore, it
is necessary to identify targets for enhancing the sensitivity
to chemotherapeutic management of HCC.
In recent years, a growing number of studies have
shown that protein phosphatase 2A (PP2A) is an import-
ant tumor suppressor. As a crucial member of the serine/
threonine protein phosphatase family widely expressed in
eukaryotic cells, PP2A is involved in the regulation of the
signal transduction, cell cycle, proliferation, differentiation,
apoptosis, and other processes [3]. PP2A-B55δ subunit,
encoded by the PPP2R2D gene, is one of four isoforms
(α, β, γ, and δ) of the PP2A B55 regulatory subunit family
[4]. The interaction between B55δ and cyclin-dependent
kinase 1 (CDK1) is reported to play a critical role in cell
cycle progression [5]. However, it is still unclear whether
B55δ enhances chemotherapy sensitivity of HCC cells by
regulating the cell cycle.
MicroRNAs (miRNAs) are small non-coding RNAs that
regulate gene expression either through mRNA degrad-
ation or translational repression [6]. The interaction with
the 3’-untranslated region (3’UTR) of the targeted mRNAs
via base pairing is thought to be the main mechanism of
miRNA function [7]. As nodes of signaling networks, miR-
NAs play a role in the regulation of metabolic homeostasis
and cancer development [8–10]. Recent studies suggest a
number of clinically significant miRNAs that may target
PP2A [11]. In view of the lack of conclusive information
on the miRNA regulation of PPP2R2D, this study aimed
to characterize the functional role of miRNA targeting of
PPP2R2D in the chemotherapy of HCC.
As a key drug in the treatment of advanced HCC [12],
cisplatin (cDDP) was selected as a representative chemo-
therapeutic drug of HCC in this study. We explored the role
of PP2A-B55δ both in regulating the cell cycle, migration,
colony formation, apoptosis, and proliferation of human
hepatoblastoma HepG2 cells and in tumor growth in xeno-
graft mice in the presence of cDDP, and we investigated the
details of the microRNA-133b (miR-133b)/PPP2R2D signal-
ing pathway. We concluded that PP2A-B55δ, under the
regulation of miR-133b, could serve as a promising target
for increasing chemotherapy sensitivity of HCC.
Methods
Bioinformatics analysis
Gene expression data of HCC cohorts were acquired
from the Gene Expression Omnibus (GEO) database
(http://www.ncbi.nlm.nih.gov/geo/). The public data-
bases microRNA.org (http://www.microrna.org/micro-
rna/getGeneForm.do) and TargetScan (http://www.tar
getscan.org/vert_70/) were used to screen for miRNAs
which might target PPP2R2D. The predicted free ener-
gies of the binding between miRNAs and their targets
were calculated by the RNAhybrid program (http://
bibiserv.techfak.uni-bielefeld.de/rnahybrid/).
Cell culture and reagents
The human hepatic cell line L02, HCC cell lines HepG2,
MHCC97H, MHCC97L, Hep3B, Huh7 and human em-
bryonic kidney 293T cells (HEK-293T) were obtained
from the Cancer Center of Sun Yat-sen University
(Guangzhou, China). The human hepatic cell line
QSG7701 and HCC cell line QGY7703 were obtained
from the College of Chemistry and Chemical Engineering,
Xiamen University (Xiamen, China). L02, QSG7701,
HepG2, Hep3B, and QGY7703 were cultured in RPMI-
1640 medium (Gibco, NY, USA) supplemented with 10 %
fetal bovine serum (FBS, Gibco) and 1 % penicillin-
streptomycin (P&S, Gibco). MHCC97H, MHCC97L, and
Huh7 were cultured in DMEM (Gibco) with 10 % FBS
and 1 % P&S. All cell lines were maintained at 37 °C in a
5 % CO2 humidified incubator (Thermo, CO, USA). cDDP
was obtained from Hansoh Pharmaceutical Co., Ltd
(Jiangsu, China).
Antibodies
The primary antibodies for PP2A-B55δ were purchased
from Abcam (MA, USA) and Santa Cruz (CA, USA).
PP2A-Aα subunit antibody was from Covance (NJ,
USA). PP2A-C subunit, phosphorylated CDK1 (p-CDK1
Tyr15), CDK1, and cleaved Caspase-3 antibodies, and
the secondary antibodies anti-rabbit IgG and anti-mouse
IgG were from Cell Signaling Technology (MA, USA).
PP2A-B55α antibody was from Merck Millipore (MA,
USA). PP2A-B56γ antibody was obtained from Thermo.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and B-cell lymphoma 2-related protein (Bcl-2) anti-
bodies were from Beyotime (Shanghai, China). Anti-
bodies for Cyclin B1, Cyclin E1, Bcl-2-associated X
protein (Bax), and proliferating cell nuclear antigen
(PCNA) were from Ruiying Bioalogical (Jiangsu, China).
The secondary antibodies anti-rat IgG and anti-goat IgG
were from Proteintech (IL, USA). The fluorescein
isothiocyanate-conjugated (FITC) rabbit anti-goat IgG
was from Liankebio (Zhejiang, China).
Quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA was extracted using TRIzol® Reagent (Ambion,
TX, USA) and reverse-transcribed into cDNA using Pri-
meScript™ RT reagent kit (TaKaRa, Otsu, Japan). qRT-
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PCR was performed with SYBR® Premix Ex Taq™ II kit
(TaKaRa) in a CFX96 Touch™ Real-Time PCR Detection
System (Bio-Rad, CA, USA) using the primers (Sangon
Biotech, Shanghai, China) shown in Additional file 1:
Table S1. Cycling conditions were 95 °C for 30 s, 40 cycles
of 95 °C for 5 s, and 60 °C for 34 s. The mRNA levels of
genes were evaluated using the 2-△△Ct relative quantification
method. ACTB (encoding β-actin) was used as a reference
control. Quantitative analysis of miRNA expression was
performed with the Bulge-Loop™ hsa-miR-133b qRT-PCR
primer set (Ribobio, Guangzhou, China). U6 snRNA was
used as a reference control.
Western blotting (WB) analysis
Cells were lysed in whole-cell lysate buffer. For phos-
phorylated protein, 1 % phosphatase inhibitor cocktail
was added to the whole-cell lysate buffer. Protein lysates
were resolved by 10 % or 12 % sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), and
then transferred to poly vinylidene fluoride (PVDF)
membranes (Pall, NY, USA). After blocking with 5 %
nonfat milk, the membranes were incubated with pri-
mary antibodies overnight at 4 °C, and then incubated
with the corresponding secondary antibodies at room
temperature for 1 h. Protein bands were visualized with
an enhanced chemiluminescence kit (Pierce, IL, USA).
The blot intensities of each band were analyzed by Ima-
geJ software (NIH, MD, USA). GAPDH was used as a
loading control.
PP2A activity assay
A Serine/Threonine Phosphatase Assay System (Pro-
mega, WI, USA) was used for measuring PP2A activities.
Following the instruction manual, collected cell lysates
were centrifuged at 1 × 105 g for 1 h at 4 °C in phosphat-
ase storage buffer. Sephadex® G-25 spin columns were
used to remove endogenous phosphate. The treated ly-
sates were added to a mixture containing PP2A reaction
buffer and phosphopeptide, and then incubated for 1 h
at 37 °C. The reaction was stopped with molybdate dye/
additive mixture. The optical density (OD) of the samples
was read using a Multiskan™ FC microplate photometer
(Thermo) at 600 nm. PP2A activity was measured in three
parallel experiments.
Immunofluorescence assay
The cells, seeded on coverslips in 12-well plates, were
fixed with freshly-prepared 4 % paraformaldehyde and
permeabilized with 0.5 % Triton X-100. After blocking
with phosphate-buffered saline (PBS) containing 1 %
BSA, the cells were treated with primary antibody over-
night and incubated with fluorescent secondary antibody
for 1 h in the dark. After extensive washing, cell nuclei
were counterstained with 4, 6-diamidino-2-phenylindole
(DAPI) for 1 min. The cells were photographed using a
confocal microscope (Olympus, Tokyo, Japan). Three in-
dependent assays were conducted; representative images
are shown.
Establishment of stable PPP2R2D-knockdown cell lines
The short hairpin RNA (shRNA) targeting the PPP2R2D
mRNA sequence (GenBank Accession No. NM_018461.4)
was designed using the Genetic Perturbation Platform
(http://www.broadinstitute.org/rnai/public/). The sense and
antisense oligonucleotides of sh2R2D (Additional file 1:
Table S1) were annealed and then ligated into lentiviral
vector pLKO.1-puro (a kind gift from Dr. Wen Chen, Sun
Yat-sen University, China) to construct the pLKO.1-
sh2R2D recombinant plasmid. The corresponding control
plasmid was pLKO.1 bearing shRNA targeting green fluor-
escent protein (pLKO.1-shGFP) [13]. The lentiviral plasmid
(pLKO.1-shGFP or pLKO.1-sh2R2D), packaging plasmid
(pCMV-delta 8.9), and envelope plasmid (VSVG) were co-
transfected into HEK-293T cells using X-tremeGENE HP
DNA transfection reagent (Roche, IN, USA). Lentiviruses
packaged in HEK-293T cells were purified and then intro-
duced into HepG2 cells using polybrene (Sigma, MO,
USA). The established cell lines (HepG2-shGFP and
HepG2-sh2R2D) were screened with 0.6 μg/ml
puromycin.
Establishment of stable PPP2R2D-overexpression cell lines
PPP2R2D full-length coding sequence (2R2Dc) was ob-
tained using the primers shown in Additional file 1:
Table S1 and incorporated into retroviral vector pBabe-
puro (a kind gift from Dr. Wen Chen) to construct the
pBabe-2R2Dc recombinant plasmid. HEK-293T cells
were co-transfected with retroviral plasmid (pBabe or
pBabe-2R2Dc) and pCL-Ampho vector in a ratio of 1:1.
HepG2 cells were then infected with retroviruses pro-
duced by HEK-293T cells. The established cell lines
(HepG2-pBabe and HepG2-2R2Dc) were screened with
0.6 μg/ml puromycin.
Cell cycle analysis
Cells were collected, fixed in 70 % ice-cold ethanol, in-
cubated with RNase, and dyed with propidium iodide
(PI). Flow cytometry (FCM, Beckman, CA, USA) was
used to analyze DNA content. The data were analyzed
using ModFit LT 3.1 (Verity Software House, ME, USA)
and cell cycle distribution was calculated. Each experi-
ment was repeated at least three times.
Cell migration assay
The migratory ability of cells was evaluated using
6.5 mm Transwell chambers with 8.0 μm pore polycar-
bonate membrane insert (Corning, NY, USA). Cells pre-
pared in FBS-free medium were seeded onto the upper
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chambers, and medium with 10 % FBS was added to the
bottom chambers as a chemoattractant. cDDP was given
to the cells 30 min later. After 12 h, migrated cells lo-
cated on the lower surface of chambers were fixed and
stained with crystal violet. The cells were photographed
using an inverted microscope and counted in 10 ran-
domly selected fields at a 200× magnification using
Image Pro-Plus software 6.0 (IPP 6.0, Media Cybernetics,
MD, USA). The assay was carried out three times.
Cell colony formation assay
To evaluate the self-renewal capacity of different cell
types, 800 cells were seeded in 6-well plates. After 24 h,
cells were treated with cDDP for 12 h and maintained in
culture for another 6 days. On day 7, the cells were
fixed, stained, and drained for taking photographs. The
colony formation areas were calculated by ImageJ. The
assay was carried out in triplicate.
Apoptosis assay
The Annexin V‑FITC Apoptosis Detection kit (Beyotime)
was used for apoptosis assays. Briefly, cells were harvested,
resuspended in Annexin V-FITC binding buffer, and
stained with Annexin V-FITC and PI in the dark. Cells
were then analyzed by FCM. FlowJo v.7.6.5 (FlowJo, OR,
USA) was used to analyze the data. The experiment was
repeated three times separately.
Cell proliferation assay
Cells were plated at a density of 8 × 103 cells/well in 96-
well plates and exposed to cDDP for 24 h. Then, 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT, Sigma) was added to each well. The OD was
measured spectrophotometrically at 570 nm using a
Multiskan™ FC microplate photometer 4 h later. The cell
growth inhibition (GI) rate was calculated as the follow-
ing formula: GI (%) = [1 − (OD570Sample −OD570Blank)/
(OD570Ctrl −OD570Blank)] × 100 %. This assay was re-
peated at least three times.
In vivo xenograft studies
BALB/c nude mice (5–7 weeks old) were obtained from
the Xiamen University Laboratory Animal Center (Xiamen,
China). All experimental procedures were approved by
the Experimental Animal Ethics Committee of Xiamen
University. The mice were randomly allocated to four
groups: pBabe-Ctrl group, 2R2Dc-Ctrl group, pBabe-
cDDP group, and 2R2Dc-cDDP group (n = 6 in each
group). A total of 5 × 106 cells (HepG2-pBabe or
HepG2-2R2Dc) were suspended in PBS with matrigel
(BD Biosciences, CA, USA) in a 1:1 ratio. These cell
suspensions were subcutaneously inoculated into the
right flank of each mouse, and the tumors were allowed
to grow for a week. Tumor width (w) and length (l) and
body weights were measured every other day. Tumor vol-
ume (V) was calculated using the formula: V = (w2 × l)/2.
A week later, the mice in the 2R2Dc-cDDP group or the
pBabe-cDDP group were injected with 1 mg/kg body
weight cDDP via tail vein every other day for three times,
respectively. All mice were sacrificed and tumors were ex-
cised on day 14. Tumor weight was recorded, and tumor
tissues were subjected to immunohistochemistry (IHC),
WB, and qRT-PCR assays.
Immunohistochemistry (IHC)
The dissected tumor tissues were fixed, embedded in
paraffin, and serially sectioned at 4 μm thickness. Sec-
tions were dewaxed, rehydrated, and antigen retrieved.
UltraSensitive™ SP (Mouse/Rabbit) IHC Kit (Maixin Bio-
tech, Fuzhou, China) was used according to the manu-
facturer’s instructions. Sections were incubated with
primary antibodies overnight followed by a secondary
antibody. Next, sections were stained with 3, 3’-diami-
nobenzidine, counterstained with hematoxylin, and
dehydrated through graded ethanol solutions. Finally,
sections were photographed using a microscope and
analyzed using IPP 6.0.
Transient transfection and luciferase reporter assay
The PPP2R2D 3’UTR fragment was amplified using the
primers shown in Additional file 1: Table S1, ligated into
the pGL3-control luciferase reporter vector (pGL3c, a
kind gift from Dr. Shimei Zhuang, Sun Yat-sen Univer-
sity, China), and confirmed by sequencing. Transfection
was performed in 96-well plates using Lipofectamine®
2000 transfection reagent (Invitrogen, CA, USA) ac-
cording to the standard protocol. Briefly, cells were
co-transfected with 50 ng pRL-TK vector and 200 ng
of either pGL3c or pGL3c-2R2D-3’UTR for 4 h. After
treatment with cDDP for 6 h, cells were analyzed using
Dual Luciferase® reporter assay system (Promega). The lu-
ciferase activities were normalized against the activity of
pGL3c.
miRNA mimic or inhibitor transfection
Cells were transfected with miRNA mimic or inhibitor
(Ribobio) according to the manufacturer’s instructions.
Briefly, cells were plated in 6-well plates and grown to
70 % confluence. For each well, 50 nM miR-133b mimic
or 100 nM inhibitor in riboFECT™ CP Buffer (Ribobio)
was mixed gently with riboFECT™ CP Reagent and
added to the cells for 12 h.
Statistics
Statistical analyses were carried out using the Statistical
Package for Social Sciences (SPSS) version 16.0 (SPSS, IL,
USA). All data were expressed as mean ± standard devi-
ation (SD). The statistical significance was determined
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using two-tailed unpaired Student’s t-test for the compari-
son of two groups and using one-way analysis of variance
(ANOVA) for the comparison of multiple groups, fol-
lowing which the statistical significance was determined
by Dunnett’s t-test. Correlation between variables was
evaluated with Pearson’s correlation for normal distribu-
tion or Spearman’s correlation for non-normal distribu-
tion. A P < 0.05 was considered statistically significant.
Results
PPP2R2D is down-regulated in HCC
In order to investigate the association between PPP2R2D
expression and HCC, we analyzed the published micro-
array datasets available from GEO database. In two dif-
ferent HCC cohorts (Accession No.: GSE59259 and
GSE6764) [14, 15], the tumor tissues exhibited relatively
low PPP2R2D expression levels (Fig. 1a). In addition,
Kaplan-Meier survival curves shown in Fig. 1b indicated
that the 5-year overall survival rates of HCC patients
(Accession No.: GSE54236) [16] with low PPP2R2D expres-
sion was lower than that with high PPP2R2D expression.
We further evaluate PPP2R2D mRNA and B55δ pro-
tein in two normal hepatic cell lines and six HCC cell
lines by qRT-PCR and WB. The data showed that the
levels of PPP2R2D mRNA and B55δ protein were signifi-
cantly suppressed in all HCC cell lines compared with
normal hepatic cell lines (Fig. 1c–d). Taken together, the
expression of PPP2R2D was down-regulated in HCC tis-
sues and cells, indicating that PPP2R2D might act as a
tumor suppressor in the chemotherapy of HCC.
The expression of B55δ is increased by cDDP in HepG2 cells
In order to explore the functional role of PPP2R2D in
the chemotherapy of HCC, HepG2 cells were chosen as
a sensitive model because of its lower expression of
PPP2R2D compared to other HCC cell lines (Fig. 1c–d).
We used cDDP, an accepted anti-tumor agent [17], in-
vestigating B55δ expression in HepG2 cells in response
to chemotherapy. PP2A activity was increased by cDDP
in a concentration- and time-dependent manner (Fig. 2a).
As shown in Fig. 2b, cDDP significantly up-regulated
the mRNA level of PPP2R2D and PPP2R2A, but not of
PPP2R1A, PPP2CA, or PPP2R5C. cDDP increased only
the expression of B55δ protein, not of the other sub-
units of PP2A (Fig. 2c). Immunofluorescence analysis
also revealed that B55δ was more strongly expressed
following cDDP treatment (Fig. 2d). Additionally, the
protein levels of B55δ were increased in cDDP-treated
Fig. 1 PPP2R2D is down-regulated in HCC. a PPP2R2D expression levels in two cohorts of HCC patients [14, 15]. The mRNA microarray data were
obtained from GEO database (Accession No.: GSE59259 and GSE6764, *P < 0.05). b Kaplan-Meier analysis showing overall survival of HCC patients
[16] with two different levels of PPP2R2D expression (Accession No.: GSE54236, PPP2R2D expression was treated as a binary variable divided into
high or low expression according to the median, Log-rank, *P < 0.05). c PPP2R2D mRNA and (d) B55δ protein levels were evaluated in normal
hepatic cell lines and HCC cell lines. The data shown in the bar graph are the mean ± SD of three independent experiments. *P < 0.01 as
compared with L02 cells; #P < 0.01 as compared with QSG7701 cells
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cells in a concentration- and time-dependent manner
(Fig. 2e). Thus, our findings suggested that cDDP in-
creased the amount of B55δ in HepG2 cells.
Knockdown of PPP2R2D partially reverses the sensitivity
of HepG2 cells to cDDP
To elucidate the crucial role that B55δ plays in sensitiz-
ing HepG2 cells to anti-cancer treatment, PPP2R2D was
knocked down. Approximately 50 % knockdown of
PPP2R2D mRNA level was achieved in HepG2-sh2R2D
cells as compared with HepG2-shGFP cells, which re-
sulted in a 2-fold decrease of B55δ protein without alter-
ation of other PP2A subunits (Additional file 2: Figure
S1A–B). G1 phase cell numbers were mildly decreased
by sh2R2D (“Ctrl” in Fig. 3a). The migratory ability and
self-renewal capacity of HepG2-sh2R2D cells were both
higher than those of HepG2-shGFP cells (“Ctrl” in
Fig. 3b–c). There was no apparent difference between
two established stable cell lines in apoptosis rate (“Ctrl”
in Fig. 3d). However, knockdown of PPP2R2D signifi-
cantly reversed G1 phase cell cycle arrest, migratory in-
hibition, cell colony area reduction, and apoptosis
induced by cDDP (Fig. 3a–d). After treatment with
cDDP, cell growth inhibition rate of HepG2-sh2R2D
cells was also markedly lower than that of HepG2-
shGFP cells (Fig. 3e). In addition, knockdown of
PPP2R2D significantly decreased the PP2A activity after
treatment with cDDP (Fig. 3f ), which correspondingly
influenced the levels of p-CDK1 and cell cycle-related
proteins Cyclin B1 and Cyclin E1 (Fig. 3g). The
apoptosis-related proteins (Bcl-2, Bax, and cleaved
Caspase-3) were in perfect agreement with the FCM re-
sults (Fig. 3h). Based on these results, we concluded
that knockdown of PPP2R2D partially reversed the sen-
sitivity of HepG2 cells to cDDP.
Overexpression of B55δ sensitizes HepG2 cells to cDDP
We further established stable cell lines of HepG2 over-
expressing B55δ and confirmed the overexpression at
both the mRNA and protein levels (Additional file 2:
Figure S1C–D). G1 phase cell numbers of HepG2-
2R2Dc cells were a little more than those of HepG2-
pBabe cells (“Ctrl” in Fig. 4a). The migratory ability and
self-renewal capacity were inhibited by overexpression of
Fig. 2 The expression of B55δ is increased by cDDP in HepG2 cells. a PP2A activity and (e) B55δ protein levels in HepG2 cells treated with 0, 1,
2.5, or 4 μg/ml cDDP for 12 h, or treated with 2.5 μg/ml cDDP for 0, 6, 12, or 24 h. b-d HepG2 cells were treated with or without 2.5 μg/ml cDDP
for 12 h. b The mRNA levels of PP2A subunits (PPP2R1A, PPP2CA, PPP2R2A, PPP2R2D and PPP2R5C). c The protein levels of PP2A-Aα, -C, -B55α,
-B55δ, and -B56γ subunits. d Immunofluorescence images of B55δ in HepG2 cells (×630 magnification; scale bar, 10 μm). Data are presented as
mean ± SD of three independent assays. *P < 0.01 as compared with cDDP-untreated group (Ctrl)
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B55δ (“Ctrl” in Fig. 4b–c). Also, there was no apparent
difference between apoptosis rates of the two stable cell
lines (“Ctrl” in Fig. 4d). Overexpression of B55δ remark-
ably exacerbated G1 phase arrest, migratory inhibition,
colony area reduction, and apoptosis induced by cDDP
(Fig. 4a–d). In addition, the proliferation of HepG2-
2R2Dc cells was inhibited more than that of HepG2-
pBabe cells after treatment with cDDP (Fig. 4e). As
shown in Fig. 4f, the level of PP2A activity in HepG2-
2R2Dc cells with cDDP treatment was higher than that
in HepG2-pBabe cells, which correspondingly influenced
the phosphorylation level of CDK1 (“p-CDK1” in Fig. 4g).
The expression levels of cell cycle-related proteins and
apoptosis-related proteins were consistent with FCM
analysis (Fig. 4g–h). To sum up, overexpression of B55δ
sensitized HepG2 cells to cDDP, so B55δ seems to play
an important role in the chemotherapy of HCC.
Overexpression of B55δ promotes the sensitivity of HCC
xenograft tumors to cDDP
To confirm the tumor suppressive function of B55δ in
vivo, tumorigenicity assays were performed. The data
showed that B55δ overexpression reduced xenograft
tumor growth (Fig. 5a). As shown in Fig. 5a–c, tumor
volume, size, and weight of the 2R2Dc-cDDP group were
significantly smaller than those of the pBabe-cDDP group.
B55δ was up-regulated in the xenograft tumor tissues
from the 2R2Dc-cDDP group (Fig. 5d–e). Furthermore,
there was a down-regulation of Cyclin B1 and PCNA, and
an up-regulation of Cyclin E1 in the 2R2Dc-cDDP group
(Fig. 5d–e, Additional file 3: Figure S2). Figure 5e shows
higher expression levels of Bax and cleaved Caspase-3
and a lower Bcl-2 level in the 2R2Dc-cDDP group.
Taken together, in vivo data supported in vitro findings
indicating that overexpression of B55δ increased the
therapeutic susceptibility of HCC xenograft tumors to
cDDP.
miR-133b regulates the expression of PPP2R2D by
binding to its 3’UTR
In order to explore the epigenetic mechanisms of B55δ
up-regulation induced by cDDP, microRNA.org and Tar-
getScan databases were used in combination to screen
for miRNAs which might target PPP2R2D. As shown in
Fig. 6a, miR-133b was found to bind to the 3’UTR of
PPP2R2D. The predicted free energy of binding was
-20.2 kcal/mol (Fig. 6b). Furthermore, the expression
level of miR-133b was significantly up-regulated in all
HCC cell lines compared with normal hepatic cell lines
(Fig. 6c), and it was inversely related to the expression of
PPP2R2D shown in Fig. 1c. Correlation analyses showed
that the expression of miR-133b was negatively corre-
lated with PPP2R2D and B55δ in vitro and in vivo
(Fig. 6d–e, Additional file 4: Figure S3). Based on these
data, we hypothesized that decreased miR-133b might
take part in cDDP-induced up-regulation of B55δ by tar-
geting its mRNA transcripts. To confirm this hypothesis,
a luciferase reporter assay was employed. The results re-
vealed that cDDP increased the luciferase activity of the
reporter construct bearing the PPP2R2D 3’UTR (Fig. 6f ).
Moreover, there was an apparent depletion of miR-133b,
with a parallel elevation of PPP2R2D, induced by cDDP
in a concentration- and time-dependent manner in
HepG2 cells (Fig. 6g). In summary, cDDP might up-
regulate PPP2R2D through decreasing the promotion of
its degradation or the inhibition of its translation by
miR-133b acting on the 3’UTR.
miR-133b participates in cell cycle regulation by targeting
PPP2R2D
To further verify the regulatory mechanism of miR-
133b towards PPP2R2D, HepG2 cells were transfected
with mimic negative control (miNC) or miR-133b
mimic (133mi). The models were verified by qRT-PCR
and WB. In response to 133mi, the levels of PPP2R2D
mRNA and B55δ protein, not of the other PP2A sub-
units, were effectively suppressed (Additional file 5:
Figure S4A–B, “Ctrl” in Fig. 7a–b). Moreover, 133mi
reversed the up-regulation of PPP2R2D and B55δ induced
by cDDP, and rescued G1 phase arrest (Fig. 7a–c). Also,
inhibitor negative control (inNC) or miR-133b inhibitor
(133in) was given to further confirm our results shown
above. 133in enhanced the expression of PPP2R2D and
B55δ, and accelerated G1 phase arrest (Additional file 5:
Figure S4C–D, Fig. 7d–f ). As a whole, our findings
(See figure on previous page.)
Fig. 3 B55δ knockdown partially reverses the sensitivity of HepG2 cells to cDDP. HepG2-shGFP and HepG2-sh2R2D cells were treated with or
without 2.5 μg/ml cDDP for 12 h. a Cell cycle distribution was analyzed by FCM. b Cell migratory ability was detected by transwell migration
assay. The migrated cells were photographed and counted (×200 magnification; scale bar, 100 μm). c Cell self-renewal capacity was measured
by colony formation assay. d Cell apoptosis was detected by Annexin V-FITC assay and analyzed by FCM. e Cell growth inhibition rate of the
two cells treated with 0–16 μg/ml cDDP for 24 h was analyzed using cell proliferation assay. f PP2A activity was determined by the Serine/
Threonine Phosphatase Assay System. g-h The expression of related proteins B55δ, p-CDK1, CDK1, Cyclin B1, Cyclin E1, Bcl-2, Bax, and cleaved
Caspase-3 was determined by WB assays. Data shown are the mean ± SD of three independent assays. *P < 0.01 as compared with Ctrl group
of HepG2-shGFP cells; #P < 0.01 as compared with cDDP group of HepG2-shGFP cells
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Fig. 4 (See legend on next page.)
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Fig. 4 Overexpression of B55δ sensitizes HepG2 cells to cDDP. HepG2-pBabe and HepG2-2R2Dc cells were treated with or without 2.5 μg/ml
cDDP for 12 h. a Cell cycle distribution, (b) migratory ability, (c) self-renewal capacity, (d) cell apoptosis, and (f) PP2A activity were detected. e Cell
growth inhibition rate of the two cells treated with 0-16 μg/ml cDDP for 24 h was analyzed. g-h Expression of B55δ, p-CDK1, CDK1, Cyclin B1,
Cyclin E1, Bcl-2, Bax, and cleaved Caspase-3 was measured. Values shown are mean ± SD of three independent experiments. * P < 0.01 as
compared with Ctrl group of HepG2-pBabe cells; #P < 0.01 as compared with cDDP group of HepG2-pBabe cells
Fig. 5 Overexpression of B55δ promotes the sensitivity of HCC xenograft tumors to cDDP. Nude mice transplanted with HepG2-pBabe or
HepG2-2R2Dc cells were injected with or without 1 mg/kg body weight cDDP every other day for 3 times. a Graph depicts the tumor volume
of the four groups (pBabe-Ctrl, pBabe-cDDP, 2R2Dc-Ctrl, and 2R2Dc-cDDP). b Representative images of tumors excised from nude mice. c Scatter plot
shows the tumor weights for the four groups. Values shown are mean ± SD of six different samples. *P < 0.01 as compared with pBabe-Ctrl
group; #P < 0.01 as compared with pBabe-cDDP group. d IHC images of sections of tumors reveal the expression of B55δ, Cyclin B1, Cyclin E1,
and PCNA (×1000 magnification; scale bar, 20 μm). e WB was performed to detect B55δ, Cyclin B1, Cyclin E1, PCNA, Bcl-2, Bax, and cleaved
Caspase-3 protein levels in 12 representative tumor tissues (n = 3 in each group)
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provided a potential molecular mechanism leading to the
up-regulation of B55δ by cDDP chemotherapy, involving
the decrease of miR-133b.
Discussion
HCC is one of the most lethal forms of cancer in the
world [18]. In recent years, molecule-targeted drugs,
such as Sorafenib and Brivanib, have been developed for
the treatment of liver cancer [19]. However, there are
few drugs designed for HCC and most targeted thera-
peutic drugs are less effective [20]. cDDP is an old drug
that is commonly used as a chemotherapeutic agent
against advanced HCC [12]. However, the sensitivity to
cDDP varies among HCC patients. Thus, the identifica-
tion of effective targets for enhancing chemotherapeutic
sensitivity is urgently required.
As a key tumor suppressor, PP2A has emerged as a
novel target in alternative therapeutic strategies in many
Fig. 6 PPP2R2D is a direct downstream target gene of miR-133b. a The schematic diagram shows the PPP2R2D 3’UTR (2R2D-3’UTR) regions
containing the binding site for miR-133b. b Predicted structure and free energy of binding between miR-133b (green) and 2R2D-3’UTR (red).
c The miR-133b expression in normal hepatic cell lines and HCC cell lines. *P < 0.01 as compared with L02 cells; #P < 0.01 as compared with
QSG7701 cells. d Pearson’s correlation analysis of miR-133b and PPP2R2D mRNA levels among HCC cell lines. e Spearman’s correlation analysis
of miR-133b and PPP2R2D mRNA levels in HCC xenograft tumors. f Luciferase activity of pGL3c-2R2D-3’UTR reporter gene in HepG2 cells treated with
or without 2.5 μg/ml cDDP for 6 h. The data shown are the mean ± SD of three parallel samples, *P < 0.01. g miR-133b and PPP2R2D mRNA levels in
HepG2 cells treated with 2.5 μg/ml cDDP for 0, 3, 6, or 12 h or treated with 0, 1, 2.5, or 4 μg/ml cDDP for 12 h. *P < 0.01 as compared with
cDDP-untreated group (Ctrl)
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cancers [21–23]. Chien et al. reported that PP2A acti-
vation is crucial for deceleration of pancreatic tumori-
genesis [24]. Furthermore, PP2A activation shows a
promising anti-tumor effect in breast cancer [25]. Our
previous studies have shown that the genetic variant -241
(-/G) (rs11453459) in the 5’-flanking region of PPP2R1A
contributes to the decreased risk of HCC in a southern
Chinese Han population [26]. Moreover, other studies
have demonstrated that the regulation of regulatory B sub-
units of PP2A (PP2A-Bs), such as B55β and B56γ, play
important roles in cancer development or treatment
[27]. In the current study, PPP2R2D expression was
found to be down-regulated in both HCC tumors and
HCC cell lines. The difference in PPP2R2D expression
between normal and tumor cells suggested it as a po-
tential biomarker for HCC. Following treatment with
cDDP, B55δ was increased. We hypothesize that in-
creased B55δ enhances the sensitivity of HCC to cDDP
chemotherapy. The current study conducted in stable
PPP2R2D-knockdown and -overexpression cell lines
Fig. 7 miR-133b participates in cell cycle regulation by targeting PPP2R2D. a-c After transfection with miNC or 133mi, HepG2 cells were treated
with or without 2.5 μg/ml cDDP for 12 h. a miR-133b and PPP2R2D mRNA levels. b Protein levels of B55δ, Cyclin B1, and Cyclin E1. c Cell cycle
distribution was analyzed by FCM. d-f HepG2 cells transfected with inNC or 133in were treated with or without cDDP. d qRT-PCR, e WB, and
(f) FCM were conducted as before. The data are expressed as mean ± SD of three independent experiments. *P < 0.01 as compared with Ctrl
group of miNC- or inNC-transfected HepG2 cells; #P < 0.01 as compared with cDDP group of miNC- or inNC-transfected HepG2 cells
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validated this conclusion. The results showed that
knockdown of B55δ markedly decreased the effect of
cDDP, while overexpression of B55δ promoted the
chemosensitivity of HepG2 cells and that of HCC
xenograft tumors. Thus, our study has shown for the
first time that PP2A holoenzyme containing the B55δ
subunit is a potential molecular target which might
enhance chemotherapy sensitivity of HCC. Further ex-
ploitation of B55δ might help patients overcome in-
sensitivity of anti-cancer agents and advance the
development of tailor-made treatments for HCC.
PP2A-B55δ is critical for the control of the entry into
and exit from mitosis. On one hand, overexpression of
B55δ blocks CDK1 activation and delays mitotic pro-
gression; on the other hand, depletion of B55δ acceler-
ates entry into mitosis [28]. As an essential phosphatase,
PP2A appears to act as a central modulator of phosphor-
ylation to generate interphase and mitosis [29]. In our
study, when B55δ was knocked down, CDK1 was par-
tially increased, which reversed the G2/M reduction and
G1 arrest induced by cDDP. In contrast, overexpression
of B55δ held HepG2 cells in G1 phase by the phosphor-
ylation of CDK1, increasing cDDP’s suppression of cell
migratory ability, self-renewal capacity, and proliferation.
The activation of PP2A plays a key initiating role in
various pathways that lead to apoptosis in cancer cells
[30, 31]. We also observed that overexpression of B55δ
in the presence of cDDP resulted in down-regulation of
the anti-apoptotic molecule Bcl-2 and up-regulation of
pro-apoptotic molecules Bax and cleaved Caspase-3.
Moreover, it was noteworthy that B55δ inhibited tumor
growth while reducing the expression of the proliferation-
related protein PCNA. These observations shed light on
the underlying molecular mechanism of B55δ in the regu-
lation of the cell cycle, and confirm the pivotal role that
B55δ plays in increasing the sensitivity to chemotherapy
in HCC.
Our previous studies showed that the transcriptional ac-
tivities of PPP2R2D and PPP2R1A were regulated by the
polymorphism and methylation through genetic and epi-
genetic mechanisms [26, 32]. To further investigate the
miRNA-mediated epigenetic mechanisms of PPP2R2D
up-regulation induced by cDDP, various approaches,
including in silico analyses of putative mRNA/miRNA
complexes, were applied. We confirmed for the first time
that miR-133b regulates PPP2R2D post-transcriptional ex-
pression and translation by binding to complementary
sequences of the 3’UTR of PPP2R2D mRNA. It has
been postulated that miRNAs can function as either
tumor suppressors or oncogenes by regulating protein-
Fig. 8 Schematic representation depicting the regulation of PP2A-B55δ by miR-133b and its role in promoting chemotherapy sensitivity of HCC
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coding genes [33, 34]. miR-133b has been revealed to
be down-regulated in Parkinson disease, human non-
small cell lung, bladder, gastric, and colorectal cancers
[35–39]. In this study, miR-133b was up-regulated in
HCC cell lines, with a corresponding down-regulation
of PPP2R2D. Thus, we speculate miR-133b might act as
an oncogenic miRNA (oncomiR) in HCC. Recently,
miRNAs have been considered as good biomarkers for
early diagnosis and therapy of HCC [33]. Inhibition of
oncomiRs has been introduced as a novel therapeutic
strategy for cancer treatment [40]. By mimicking or
inhibiting miR-133b, our study elucidated the miR-
133b/PPP2R2D signaling pathway involved in cDDP
chemotherapy. Taken together, these results suggest
that miR-133b may serve as a gene-specific biomarker
for estimating the prognosis of HCC. It would be of
great interest to further investigate the functional
characterization and regulatory mechanism of miR-
133b and its derepression of PP2A-B55δ synthesis and
function in the chemotherapy of HCC in both animal
models and clinical samples.
Conclusions
In summary, our current studies offer a new insight into
the underlying mechanism of chemotherapy sensitivity
of HCC and a possible target for intervention. PP2A-
B55δ, under the regulation of miR-133b, modulates cell
cycle progression by counteracting the activation of
CDK1, and influences cell migration, colony formation,
apoptosis, and proliferation both in vitro and in vivo,
thus affecting the therapeutic response to cDDP (Fig. 8).
Consequently, our findings suggest that PP2A-B55δ
might be a potential therapeutic target for increasing the
sensitivity of HCC to chemotherapy and that inhibition
regulation of miR-133b may be an important aspect of
using this target.
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Additional file 1: Table S1. Primers used in this study. (DOC 54 kb)
Additional file 2: Figure S1. The stable PPP2R2D-knockdown and
-overexpression cell lines were verified by qRT-PCR and WB. The mRNA
levels of a panel of PP2A subunits: PPP2R1A, PPP2CA, PPP2R2A, PPP2R2D,
and PPP2R5C were detected in A HepG2-shGFP and HepG2-sh2R2D cells,
and C HepG2-pBabe and HepG2-2R2Dc cells (*P < 0.01 as compared with
HepG2-shGFP or HepG2-pBabe cells). The protein levels of PP2A subunits
(PP2A-Aα, -C, -B55α, -B55δ, and -B56γ) were measured in B HepG2-shGFP
and HepG2-sh2R2D cells, and D HepG2-pBabe and HepG2-2R2Dc cells.
(TIF 1211 kb)
Additional file 3: Figure S2. Quantitative immunohistochemical
assessment of protein levels in xenograft tumors with or without cDDP
treatment. The histogram shows the amounts of B55δ, Cyclin B1, Cyclin E1,
and PCNA proteins determined by IPP 6.0 analysis of the micrographs of
Fig. 5d. *P < 0.01 as compared with Ctrl group of HepG2-pBabe cells.
#P < 0.01 as compared with cDDP group of HepG2-pBabe cells.
(TIF 528 kb)
Additional file 4: Figure S3. Correlation analyses of miR-133b and
B55δ protein expression in vitro and in vivo. A Pearson’s correlation ana-
lysis of miR-133b and B55δ among HCC cell lines. B Spearman’s
correlation analysis of miR-133b and B55δ in HCC xenograft tumors.
(TIF 450 kb)
Additional file 5: Figure S4. The miR-133b mimic or inhibitor models
were verified by qRT-PCR and WB. The mRNA levels of PP2A subunits:
PPP2R1A, PPP2CA, PPP2R2A, PPP2R2D, and PPP2R5C were detected in
HepG2 cells A transfected with miNC or 133mi, or C transfected with
inNC or 133in (*P < 0.01 as compared with miNC- or inNC-transfected
HepG2 cells). The protein levels of PP2A subunits (PP2A-Aα, -C, -B55α,
-B55δ, and -B56γ) were measured in HepG2 cells B transfected with miNC
or 133mi, or D transfected with inNC or 133in. (TIF 1102 kb)
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